We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-0.71%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$168M
AUM Growth
-$5.13M
Cap. Flow
+$3.65M
Cap. Flow %
2.17%
Top 10 Hldgs %
74.37%
Holding
57
New
9
Increased
8
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.3M
2
CGEM icon
Cullinan Oncology
CGEM
+$2.44M
3
NKTR icon
Nektar Therapeutics
NKTR
+$1.91M
4
ELTX icon
Elicio Therapeutics
ELTX
+$1.17M
5
ALKS icon
Alkermes
ALKS
+$716K

Top Sells

Rank Stock Value
1
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$5.4M
2
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$2.97M
3
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$763K
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$384K
5
STOK icon
Stoke Therapeutics
STOK
+$285K

Sector Composition

Rank Sector Weight
1 Healthcare 96.34%
2 Energy 1.49%
3 Consumer Staples 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELTX icon
26
Elicio Therapeutics
ELTX
$78.8M
$1.09M 0.65%
+6,062
New +$1.17M
ETRN
27
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.09M 0.64%
133,050
– –
KALV
28
DELISTED
KalVista Pharmaceuticals
KALV
$1.03M 0.61%
40,000
+10,000
+33% +$263K
CLR
29
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$999K 0.59%
38,600
– –
ARVN icon
30
Arvinas
ARVN
$518M
$992K 0.59%
15,000
– –
GTHX
31
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$962K 0.57%
40,000
– –
CFRX
32
DELISTED
ContraFect Corporation
CFRX
$960K 0.57%
2,500
– –
OVV icon
33
Ovintiv
OVV
$17.5B
$818K 0.49%
34,350
– –
NARI
34
DELISTED
Inari Medical, Inc. Common Stock
NARI
$749K 0.44%
7,000
– –
TGTX icon
35
TG Therapeutics
TGTX
$8.58B
$723K 0.43%
15,000
– –
AWH
36
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$696K 0.41%
6,874
-49,133
-88% -$5.4M
BHVN
37
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$684K 0.41%
10,000
– –
PGNY icon
38
Progyny
PGNY
$2.44B
$668K 0.4%
15,000
– –
ALKS icon
39
Alkermes
ALKS
$8.82B
$654K 0.39%
+35,000
New +$716K
PXD
40
DELISTED
Pioneer Natural Resource Co.
PXD
$604K 0.36%
3,800
– –
STOK icon
41
Stoke Therapeutics
STOK
$1.82B
$583K 0.35%
15,000
-5,000
-25% -$285K
XNCR icon
42
Xencor
XNCR
$1.44B
$530K 0.31%
12,300
– –
LSF icon
43
Laird Superfood
LSF
$46.2M
$525K 0.31%
+14,000
New +$595K
TBIO
44
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$495K 0.29%
30,000
– –
FOLD
45
DELISTED
Amicus Therapeutics
FOLD
$375K 0.22%
38,000
– –
APLS
46
DELISTED
Apellis Pharmaceuticals
APLS
$343K 0.2%
8,000
– –
IFRX icon
47
InflaRx
IFRX
$256M
$273K 0.16%
70,000
– –
ARQT icon
48
Arcutis Biotherapeutics
ARQT
$3.42B
$260K 0.15%
+9,000
New +$281K
PTGX icon
49
Protagonist Therapeutics
PTGX
$8.75B
$259K 0.15%
+10,000
New +$253K
DRNA
50
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$256K 0.15%
10,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Birchview Capital held 57 positions worth $168M, down 3% from $174M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Birchview Capital's Q1 2021 filing shows 9 new, 8 increased, 4 reduced and 3 closed positions. Its largest new stake was Cullinan Oncology: 60,114 shares worth $2.5M. The largest sale was Aspira Women's Health Inc. Common Stock, an estimated $5.4M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2021 buy was Cullinan Oncology: 60,114 shares worth $2.5M.
  • Birchview Capital added most to Acadia Pharmaceuticals in Q1 2021, an estimated $3.3M increase.
  • Birchview Capital's biggest Q1 2021 reduction was Aspira Women's Health Inc. Common Stock, cutting an estimated $5.4M.
  • Birchview Capital fully exited Oxford Immunotec Global PLC Ordinary Shares in Q1 2021, selling an estimated $2.97M.
  • Birchview Capital's ten largest holdings make up 74% of its $168M portfolio in Q1 2021.
  • Birchview Capital opened 9 new positions and closed 3 in Q1 2021.
  • Birchview Capital's portfolio value fell 3% quarter-over-quarter to $168M.

Based on Birchview Capital's 13F filing for Q1 2021, filed 14 May 2021.